Sarepta Gene Therapy Setbacks

Order byBest matchMost fresh

Sarepta, Gene Therapy

Sarepta's Setback Deepens With Another Gene Therapy Fatality

In response to these safety concerns, the U.S Food and Drug Administration (FDA) has requested that the label include a black box warning for acute liver injury (ALI) and acute liver failure (ALF), a...

· 1d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

STAT · 2d

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

· 1d

Sarepta tells FDA it won’t halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics said late Friday it won’t comply with a request from the Food and Drug Administration to halt all shipments of its gene therapy following the death of a third patient r...

· 1d

Sarepta Therapeutics crisis is huge blow to Duchenne families, company

· 2d

Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says

3don MSN

Sarepta to cut 500 jobs after gene therapy setback, shares jump

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys. Its shares shot up about 40% in extended trading,

Seeking Alpha6y

Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD

Sarepta Gains After Pfizer Suffers A Setback With Gene Therapy For DMD Jul. 09, 2019 8:08 PM ET Sarepta Therapeutics, Inc. (SRPT) Stock PFE , SRPT 9 Comments 4 Likes Terry Chrisomalis

MedCity News1y

Pfizer & Sarepta Gene Therapies Both Failed Phase 3, But Analysts ...

A Pfizer gene therapy for Duchenne muscular dystrophy failed its Phase 3 clinical trial. But analysts draw distinctions between that therapy and Sarepta Therapeutics’ Elevidys, which awaits an ...

3don MSN

Sarepta to cut 500 jobs, add black-box warning on gene therapy

Sarepta Therapeutics will cut 500 jobs and add a serious warning on the label of its muscle-disorder gene therapy Elevidys, the drugmaker said on Wednesday, following the recent deaths of two patients who were on the medicine.

Business Insider1y

Sarepta Therapeutics Poised to Lead DMD Gene Therapy Market Following ...

Barclays analyst Carter Gould maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a price target of...